BDSX · Company research
Biodesix, Inc. Common Stock (BDSX): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
20records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Biodesix Adds Digital Diagnostics to Lung Pipeline, Creating New Growth Platform Combining Blood and Imaging Biomarkers | Biodesix announced a strategic partnership with Vanderbilt University to develop a radiomics-based test for lung nodule risk assessment that combines blood-based and imaging biomarkers using AI. The first product is expected to be commercially available in 2028, with initial data presented at RSNA in December 2026. This initiative expands Biodesix's lung diagnostics platform and positions the company to develop multimodal solutions across various pulmonary diseases. | View source ↗ | GlobeNewswire Inc. | Oct 19, 2026 | bullish | 1 | 1 |
| Biodesix (BDSX) Stock Sees Fair Value Lift As Analysts Back MRD Growth - Yahoo Finance | Biodesix (BDSX) Stock Sees Fair Value Lift As Analysts Back MRD Growth Yahoo Finance | View source ↗ | Yahoo Finance | Oct 15, 2026 | neutral | 0 | 0.6 |
| Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026 | Biodesix announced multiple presentations at CHEST 2026 showcasing real-world evidence for integrating Nodify Lung blood-based testing into routine lung nodule management. The presentations include sponsored research comparing biomarkers with PET imaging, independent studies on patient follow-up adherence, and analyses from the CLARIFY study involving over 2,000 patients. The company is demonstrating how blood-based biomarkers can be incorporated into structured care pathways alongside imaging. | View source ↗ | GlobeNewswire Inc. | Oct 13, 2026 | bullish | 1 | 1 |
| Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026 | Biodesix announced multiple presentations at CHEST 2026 showcasing real-world evidence for integrating Nodify Lung blood-based testing into routine lung nodule management. The presentations include sponsored research comparing biomarkers with PET imaging, independent studies on patient follow-up adherence, and analyses from the CLARIFY study involving over 2,000 patients. The company is demonstrating how blood-based biomarkers can be incorporated into structured care pathways alongside imaging. | View source ↗ | GlobeNewswire Inc. | Oct 13, 2026 | bullish | 1 | 1 |
| More than 2,000 patients received a blood test to assess lung nodules in routine care. - Stock Titan | More than 2,000 patients received a blood test to assess lung nodules in routine care. Stock Titan | View source ↗ | Stock Titan | Oct 13, 2026 | neutral | 0 | 0.6 |
| Biodesix Inc (NASDAQ: BDSX) Stock Price, News & Analysis - kalkine.ca | Biodesix Inc (NASDAQ: BDSX) Stock Price, News & Analysis kalkine.ca | View source ↗ | kalkine.ca | Oct 5, 2026 | neutral | 0 | 0.6 |
| Beat the Market Like Zacks: Thermo Fisher, Cricut, Shopify in Focus | Zacks Research showcased strong performance across its various investment portfolios and rating systems during the week ended October 2, 2026. Multiple stocks received upgrades and delivered significant gains, including CRCT and PGEN surging 32% and 30.8% respectively following recommendation upgrades. The Zacks Rank #1 portfolio outperformed the S&P 500 by 2.3 percentage points year-to-date, while the Focus List portfolio returned 19.86% versus 13.14% for the S&P 500 through August 31, 2026. | View source ↗ | Zacks Investment Research | Oct 5, 2026 | bullish | 1 | 1 |
| Converting 1,360 stock units leaves Biodesix (BDSX) chairman with 26,743 shares held directly. - Stock Titan | Converting 1,360 stock units leaves Biodesix (BDSX) chairman with 26,743 shares held directly. Stock Titan | View source ↗ | Stock Titan | Oct 2, 2026 | neutral | 0 | 0.6 |
| Biodesix, Inc. (NASDAQ:BDSX) Stock Has Average Target Price of $35.00 - MarketBeat | Biodesix, Inc. (NASDAQ:BDSX) Stock Has Average Target Price of $35.00 MarketBeat | View source ↗ | MarketBeat | Oct 2, 2026 | neutral | 0 | 0.6 |
| After cancer treatment, monitoring may reach patients without tumor tissue - Stock Titan | After cancer treatment, monitoring may reach patients without tumor tissue Stock Titan | View source ↗ | Stock Titan | Sep 24, 2026 | neutral | 0 | 0.6 |
| Biodesix (BDSX) Stock Gets Fair Value Boost On Revenue And Margin Optimism - Yahoo Finance | Biodesix (BDSX) Stock Gets Fair Value Boost On Revenue And Margin Optimism Yahoo Finance | View source ↗ | Yahoo Finance | Sep 18, 2026 | neutral | 0 | 0.6 |
| Biodesix: Growing Fast While Trading Below Many Diagnostics Peers (NASDAQ:BDSX) - Seeking Alpha | Biodesix: Growing Fast While Trading Below Many Diagnostics Peers (NASDAQ:BDSX) Seeking Alpha | View source ↗ | Seeking Alpha | Sep 10, 2026 | neutral | 0 | 0.6 |
| BioDesix (NASDAQ:BDSX) Passes Minervini Trend Template but Setup Quality Remains Weak - ChartMill | BioDesix (NASDAQ:BDSX) Passes Minervini Trend Template but Setup Quality Remains Weak ChartMill | View source ↗ | ChartMill | Sep 2, 2026 | neutral | 0 | 0.6 |
| $BDSX stock is up 14% today. Here's what we see in our data. - Quiver Quantitative | $BDSX stock is up 14% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 25, 2026 | neutral | 0 | 0.6 |
| Insider Purchase: 10% owner at $BDSX Buys 15,000 Shares | BDSX Stock News - Quiver Quantitative | Insider Purchase: 10% owner at $BDSX Buys 15,000 Shares | BDSX Stock News Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 13, 2026 | neutral | 0 | 0.6 |
| Earnings Update: Here's Why Analysts Just Lifted Their Biodesix, Inc. (NASDAQ:BDSX) Price Target To US$32.67 - Simply Wall Street | Earnings Update: Here's Why Analysts Just Lifted Their Biodesix, Inc. (NASDAQ:BDSX) Price Target To US$32.67 Simply Wall Street | View source ↗ | Simply Wall Street | Aug 8, 2026 | neutral | 0 | 0.6 |
| BDSX Forecast — Price Target — Prediction for 2027 - TradingView | BDSX Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 26, 2026 | neutral | 0 | 0.6 |
| Biodesix (BDSX) Stock Gets Fair Value Bump As Analysts Back Growth Path - Yahoo Finance | Biodesix (BDSX) Stock Gets Fair Value Bump As Analysts Back Growth Path Yahoo Finance | View source ↗ | Yahoo Finance | Jun 26, 2026 | neutral | 0 | 0.6 |
| Is Biodesix (BDSX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance | Is Biodesix (BDSX) Stock Outpacing Its Medical Peers This Year? Yahoo Finance | View source ↗ | Yahoo Finance | Mar 19, 2026 | neutral | 0 | 0.6 |
| This Diagnostics Stock Is Surging 23% Pre-Market Today – Here’s Why - Stocktwits | This Diagnostics Stock Is Surging 23% Pre-Market Today – Here’s Why Stocktwits | View source ↗ | Stocktwits | Jan 12, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.